SCRIPPS RESEARCH
INSTITUTIONAL BIOSAFETY COMMITTEE
MEETING MINUTES
August 12, 2026

I. MEETING

The Institutional Biosafety Committee (IBC) of Scripps Research held a meeting via videoconference August 12, 2026, commencing at 2 p.m. Pacific Time. The meeting was held pursuant to notice duly given and a quorum was present.

Committee Members Present		Committee Members Absent	Others Present
Juan Carlos de la Torre	Michael Bobardt	Jim Gohres	Alanna Rutan
Carolina Esquer	Cheryl Andreoli	Luke Leman	
Elyse Walk	Elizabeth Montano		
Roberto Aiolfi	Lorena Garcia Menendez		
Raphael Park	Stephen Munday		
Smita Chopade			
Case McNamara			

I. REVIEW OF PREVIOUS MEETING MINUTES

The Committee voted unanimously to approve the minutes of the July 08, 2026 IBC Meeting.

II. ANNOUNCEMENTS

None.

III. BIOSAFETY OFFICER & IBC ADMINISTRATOR'S REPORT

Alanna Rutan, Scripps Research's Chief Compliance Counsel, provided the Committee with an overview of the newly issued USG Policy for Stopping High-Risk Life Sciences Research.

IV. CONFLICT OF INTEREST

None.

V. REVIEW OF PROTOCOLS

Summary of Discussions: Summaries of each research proposal were thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

FULL COMMITTEE REVIEW

NEW

1. IBC Protocol #:	**08-12-26-03, Zhang, Meng**
Title of Study:	Mammalian Tissue Protocol
Department:	Molecular & Cellular Biology
Primary Reviewer:	Elyse Walk
Secondary Reviewer:	Cheryl Andreoli
NIH Guidelines:	III-E-1

Agents/Materials: Human cell lines.
Biosafety Level: BSL-2
Animal work: ☐Yes ☒No
Biosafety Inspection: Inspection of CHWL 258 completed on 7/30/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Regulatory Assessment
NIH guideline IIID needs to be removed.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

2. IBC Protocol #: **08-12-26-04, Lairson, Luke**
Title of Study: Diphtheria Toxin for use in Regulatory T cell and related rodent cell depletion models
Department: Chemistry
Primary Reviewer: Smita Chopade
Secondary Reviewer: Michael Bobardt
NIH Guidelines: III-B, III-F
Agents/Materials: Diphtheria Toxin.
Biosafety Level: BSL-2+, ABSL-2
Animal work: ☒Yes ☐No
Biosafety Inspection: Inspection of BCC 515 completed on 10/21/25.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information
Language regarding ABSL-2 containment needs to reflect ABSL-1.

Location of Study
The biosafety level of the room where animal work is performed needs to be changed to ABSL-1 from ABSL-2. The BSL2+ space is actually BSL-2, and the protocol requires edits to reflect that.

Regulatory Assessment
NIH section requires III-B to be removed, and III-D-4 to be selected.

Exposure Control
Animal area disinfection needs to be selected, and BSL2+ PPE deselected.

DURC
Under result of assessment, Category 1 needs to be changed to Neither.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

RENEWALS

1. IBC Protocol #:	**08-12-26-01, Ye, Li**
Title of Study:	Central control of metabolism
Department:	Neuroscience
Primary Reviewer:	Case McNamara
Secondary Reviewer:	Smita Chopade
NIH Guidelines:	III-D-1, III-D-2, III-D-3, III-D-4-a
Agents/Materials:	Adeno-associated virus, lentivirus, glycan-deficient rabies virus, Canine Adenovirus, HSV1 strain H129, human cell lines.
Biosafety Level:	BSL-2, ABSL-1
Animal work:	☒Yes ☐No
Biosafety Inspection:	Inspection of DNC 254, 246 completed on 7/13/26.
Training:	Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Location of Study
The location of the ABSL-2 work needs to be determined, and the protocol updated to reflect that.

Infectious Agents
The animal biosafety level of the room where HSV1 H129 is being worked on needs to be determined, and the protocol updated to reflect that.

Toxins
The LD_{50} for lipopolysaccharide needs to be confirmed.

Study Design/Project Description
The door placard needs to be updated.

Risk Assessment
The route of transmission for rabies needs to be confirmed.

Exposure Control
Animal area disinfection needs to be selected.

Review outcome: Not approved; Revisions to be re-reviewed by designated member review.

2. IBC Protocol #:	**08-12-26-02, Lamia, Katja**
Title of Study:	The Role of Cryptochromes and Circadian Clocks in Cellular and Organismal Metabolism
Department:	Molecular & Cellular Biology
Primary Reviewer:	Roberto Aiolfi
Secondary Reviewer:	Case McNamara
NIH Guidelines:	III-D-1, III-D-2, III-D-3, III-D-4-b
Agents/Materials:	E. coli, lentivirus, adenovirus, retrovirus, human cell lines.
Biosafety Level:	BSL-2+, ABSL-2
Animal work:	☒Yes ☐No
Biosafety Inspection:	Inspection of MB 219B completed on 7/23/26.
Training:	Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information
There is a discrepancy between whether the work performed is BSL2+ or BSL2; this needs to be clarified.

Study Design/Project Description
A detailed description of the adenoviral work is needed.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

3. IBC Protocol #:	**08-12-26-05, Roberto, Marisa**
Title of Study:	Neurobiology of alcohol use and stress disorders in rodent models
Department:	Translational Medicine
Primary Reviewer:	Michael Bobardt
Secondary Reviewer:	Elyse Walk
NIH Guidelines:	III-D-1, III-D-4-a
Agents/Materials:	Lentivirus, Pseudotyped rabies virus, adeno-associated virus.
Biosafety Level:	BSL-2+, ABSL-2
Animal work:	☒Yes ☐No
Biosafety Inspection:	Inspection of SR 305, 101J completed on 7/13/26.
Training:	Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Location of Study
The location of the animal work needs to be added.

Regulatory Assessment
The NIH guideline III-D-4b needs to be added.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

4. IBC Protocol #:	**08-12-26-06, Yates, John**
Title of Study:	Knock Down of Target Proteins and Analysis of Protein-Protein Interactions in Cell Culture
Department:	ISCB
Primary Reviewer:	Raphael Park
Secondary Reviewer:	Roberto Aiolfi
NIH Guidelines:	III-D-1, III-D-2, III-E-1
Agents/Materials:	Lentivirus, human cell lines.
Biosafety Level:	BSL-2+
Animal work:	☐Yes ☒No
Biosafety Inspection:	Inspection of SR 308X completed on7/14/26.
Training:	Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Location of Study
The table needs to be completed for the laboratory where most experiments occur and the location of proteomics needs to be added.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

5. IBC Protocol #:	**08-12-26-07, Wilson, Ian**
Title of Study:	Parasitic Disease Studies
Department:	ISCB
Primary Reviewer:	Cheryl Andreoli
Secondary Reviewer:	Elyse Walk
NIH Guidelines:	III-D-2
Agents/Materials:	E. coli, human cell lines.
Biosafety Level:	BSL-2
Animal work:	☐Yes ☒No
Biosafety Inspection:	Inspection of BCC 223, 237 completed on 7/16/26.
Training:	Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Exposure Control
It needs to be clarified whether the lab autoclaves their own waste or just equipment.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

BIOSAFETY REVIEW

1. IBC Protocol #:	**11-13-19-06, Grotjahn, Danielle**
Title of Study:	Probing pathogenic mechanisms of mitochondrial fragmentation in neurodegenerative disease
Department:	ISCB
NIH Guidelines:	III-D, III-E-1
Agents/Materials:	Human cell lines.
Biosafety Level:	BSL-2
Animal work:	☐Yes ☒No
Training:	Training verified and on record.
REVIEW OUTCOME:	**Approved.**

2. IBC Protocol #:	**08-14-24-01, de Carvalho, Renan**
Title of Study:	Understanding the longevity of immune responses
Department:	Immunology & Microbiology
NIH Guidelines:	III-D-3
Agents/Materials:	Adeno associated virus, E. coli, Influenza PR8, Lymphocytic choriomeningitis virus, lentivirus, norovirus, Plasmodium chabaudi, retrovirus, rotavirus, SARS-CoV-2.
Biosafety Level:	BSL-2+, ABSL-2

Animal work: ☒Yes ☐No
Training: Training verified and on record.
REVIEW OUTCOME: **Approved.**

3. IBC Protocol #: **01-14-26-01, Schultz, Peter**
Title of Study: Creating synthetic molecules using tools of organic physics, synthetic chemistry and biological systems to develop protein therapeutics, synthetic vaccines and screening approaches
Department: Chemistry
NIH Guidelines: III-D-2
Agents/Materials: E. coli, Hepatitis B virus, Lentivirus, Pseudomonas aeruginosa, Recombinant baculovirus, Staphylococcus aureus, Virioids, human cell lines, primary human cells.
Biosafety Level: BSL-2
Animal work: ☐Yes ☒No
Training: Training verified and on record.
REVIEW OUTCOME: **Approved.**

VI. ADJOURNMENT
The next scheduled IBC meeting is **Wednesday, September 9, 2026,** via Teams at 2:00 PM. If full committee review protocols are not received by the next deadline date and there are no agenda items for full committee discussion, the meeting will be canceled. Members will be notified via e-mail of meeting cancellations one week before the scheduled meeting.